

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2016.

Commission File Number: 001-37384

GALAPAGOS NV

(Translation of registrant's name into English)

Generaal De Wittelaan L11 A3

2800 Mechelen, Belgium

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [x] Form 40-F []

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

On October 12, 2016 the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated October 12, 2016

The information contained in this report on Form 6-K, including the exhibit, is hereby incorporated by reference into the Company's Registration Statements on Forms F-3 (File No. 333-211765) and S-8 (File Nos. 333-204567, 333-208697, and 333-211834).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GALAPAGOS NV

(Registrant)

Date: November 9, 2016

/s/ XAVIER MAES

Xavier Maes

Company Secretary



Galapagos

Transparency notification - FMR LLC reaches 10% threshold

Mechelen, Belgium; 12 October 2016, 22.00 CET - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Fidelity Management & Research (FMR) LLC.

Pursuant to Belgian transparency legislation^[1], Galapagos received a transparency notification on 7 October 2016 from FMR LLC, who notified that it holds 4,616,982 of Galapagos' voting rights, consisting of shares (4,580,182) and equivalent financial instruments (36,800), through its subsidiary undertakings Fidelity Management & Research Company and FMR Co., Inc. This represents 10% of Galapagos' currently outstanding 46,169,828 shares, and is an increase compared to FMR LLC's previous transparency notification of 19 May 2015. FMR LLC reached the 10% threshold of Galapagos' voting rights by acquiring additional voting securities on 3 October 2016. The full transparency notice is available on the Galapagos website.

About Galapagos

Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises a pipeline of Phase 3, Phase 2, Phase 1, pre-clinical, and discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 460 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. More information at www.glp.com.

Contacts

Investors:

Elizabeth Goodwin
VP IR & Corporate
Communications
+1 781 460 1784

Media:

Evelyn Fox
Director Communications
+31 6 53 591 999
communications@glpg.com

Paul van der Horst
Director IR & Business
Development
+31 6 53 725 199
ir@glpg.com

Forward-looking statements

This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.

^[1] Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market.